DGAP-Adhoc: Biotest AG: Biotest AG sets the subscription price and the offer price for the new preferred shares at EUR 52.00 per preferred share

Biotest AG / Key word(s): Capital Increase

10.06.2013 19:05

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

/
Ad-hoc RELEASE
Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)

Biotest AG sets the subscription price and the offer price for the new
preferred shares at EUR 52.00 per preferred share

Dreieich, 10 June 2013 - The management board of Biotest AG decided today,
in consultation with equinet Bank AG, on the further parameters for the
capital increase against cash contribution announced on 10 June 2013. The
subscription price for the new preferred shares to be offered to existing
shareholders in the subscription offer and the offer price for the new
preferred shares offered by means of the Pre-placement to qualified
investors in Germany and in other European countries has been set at EUR
52.00 per preferred share.

Up to 1,461,909 new no-par value preferred bearer shares (shares without
nominal value) will be issued representing a notional interest of EUR 2.56
in Biotest AG and carrying full dividend rights from 1 January 2013 ('New
Shares').

All 1,461,909 New Shares have been placed pursuant to the Pre-placement.
Ca. 59 % of the New Shares allocated for investors in the Pre-Placement
will be subject to a claw-back in case of an exercise of subscription
rights by those existing shareholders which have not transferred their
subscription rights to equinet Bank AG.

The subscription period is expected to begin on 12 June and end on 25 June
2013 (inclusive). The delivery of the New Shares is expected to take place
on 1 July 2013.

The gross proceeds of the Company will amount to approximately EUR 76.0
million.

Biotest Aktiengesellschaft
The Management Board
Biotest AG
Landsteinerstr. 5
63303 Dreieich
www.biotest.de

ISIN: DE0005227235; DE0005227201
WKN: 522723; 522720

This publication constitutes neither an offer to sell nor a solicitation to
buy or subscribe to securities. The subscription offer as a public offering
in Germany and Luxembourg will be made solely on the basis of the
securities prospectus dated 10 June 2013 as approved by the Bundesanstalt
für Finanzdienstleistungsaufsicht (BaFin). The information legally required
to be provided to investors is contained only in the securities prospectus.
The securities prospectus is available free of charge on the internet at
the website of the issuer (www.biotest.de) and during normal business hours
at the issuer, on a date to be determined.

The information contained herein is not for distribution, directly or
indirectly, in or into the United States of America and must not be
distributed to U.S. persons (as defined in Regulation S of the U.S.
Securities Act of 1933, as amended ('Securities Act')) or publications with
a general circulation in the United States of America. This publication
constitutes neither an offer to sell nor a solicitation to buy or subscribe
to securities in the United States of America. The securities have not been
and will not be registered under the Securities Act and may not be offered
or sold in the United States of America absent registration or an exemption
from registration under the Securities Act. The Issuer does not intend to
register any portion of the offering in the United States of America or to
conduct a public offering of the securities in the United States of
America.

No prospectus has been or will be approved for publication in the United
Kingdom in respect of the securities to which this publication relates.
Consequently, this publication is being distributed only to, and is
directed only at, Qualified Investors (as defined below) who (i) are
persons who have professional experience in matters relating to investments
falling within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005, as amended (the 'Order'), (ii) are high
net worth entities falling within Articles 49(a) to (d) of the Order, or
(iii) other persons to whom it may otherwise lawfully be communicated (all
such persons together being referred to as 'relevant persons').
Furthermore, this publication is only addressed to and directed at persons
in member states of the European Economic Area (other than in Germany) who
are 'qualified investors' within the meaning of Article 2(1)(e) of the
Prospectus Directive (Directive 2003/71/EC as amended) ('Qualified
Investors'). Any investment or investment activity to which this
publication relates is only available to and will only be engaged in with
(i) in the United Kingdom, relevant persons who are also Qualified
Investors, and (ii) in any other member state of the European Economic Area
(other than in Germany and Luxembourg), Qualified Investors. Any other
persons who receive this publication in the European Economic Area (other
than in Germany or Luxembourg) should not rely on or act upon it.

The information contained herein is not for publication or distribution,
directly or indirectly, in or into the United States of America, Canada,
Japan or Australia.

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has about 1.800
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart

---------------------------------------------------------------------------

Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------